Mr. Ralston will be available for meetings with potential investors and partners to further discuss company updates during the JP Morgan Healthcare Conference 2012 being held in San Francisco, CA, January 9-12, 2012.About MacuCLEAR, Inc. MacuCLEAR, Inc. is a clinical-stage specialty pharmaceutical company focused on developing innovative treatments for vascular and retinal diseases of the eye. Its lead compound MC-1101 is a novel, topically delivered eye drop drug for treating and stopping the progression of age-related macular degeneration (AMD) from the early-stage (Dry AMD) to the late-stage (Wet AMD) by improving ocular blood flow. The active ingredient of MC-1101 has been previously approved by the FDA as an oral antihypertensive drug. MC-1101 has been granted 505 (b) 2 status and has formal Fast Track designation by the FDA. In addition to MC-1101, MacuCLEAR's portfolio includes 11 compounds that are being developed for diabetic retinopathy, second-generation treatment for AMD and other vascular diseases of the eye. George C.Y. Chiou, Ph.D., who led the development of Timolol, a pioneering treatment for glaucoma, invented this technology at Texas A&M University. Founded in 2006, MacuCLEAR is a privately held Plano, TX-based company. For additional information, please visit www.macuclear.com. About Age-Related Macular Degeneration AMD is the leading cause for blindness in the world in people 50 and older. Dry AMD afflicts 90 percent of AMD sufferers and currently has no approved drug treatments. Media Contact: Tiberend Strategic Advisors, Inc.(212) 827-0020Andrew Mialach, firstname.lastname@example.org Claire Sojda, email@example.com SOURCE MacuCLEAR, Inc.